Literature DB >> 22070636

Metabolic syndrome and bipolar disorder: what should psychiatrists know?

Karla M de Almeida1, Camila L R L Moreira, Beny Lafer.   

Abstract

This paper reviews the association between bipolar disorder (BD) and metabolic syndrome (MetS), focusing on the etiopathogenetic and pathophysiological aspects of this association and on the recommendations for preventing and managing MetS in patients with BD. We conducted a nonsystematic literature review by means of a MEDLINE search. The exact causal relationship between MetS and BD is still uncertain. The side effects of psychotropic medications may be a major contributor to the increased rates of MetS in patients with BD. Other factors such as unhealthy lifestyles, common neuroendocrine and immuno-inflammatory abnormalities, and genetic vulnerability may also play a role in explaining the high rates of MetS in BD. Strategies to prevent and treat the MetS and its cardiovascular consequences in patients with BD include accurate screening and monitoring of the patient and appropriate psychoeducation on weight control, healthy nutrition, and increased physical activity. When deciding on pharmacological therapy for the treatment of the components of the MetS, drug interactions and the effects of the medications on mood must be taken into account.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22070636      PMCID: PMC6493593          DOI: 10.1111/j.1755-5949.2011.00240.x

Source DB:  PubMed          Journal:  CNS Neurosci Ther        ISSN: 1755-5930            Impact factor:   5.243


  7 in total

1.  Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.

Authors:  Lakshmi N Yatham; Sidney H Kennedy; Sagar V Parikh; Ayal Schaffer; David J Bond; Benicio N Frey; Verinder Sharma; Benjamin I Goldstein; Soham Rej; Serge Beaulieu; Martin Alda; Glenda MacQueen; Roumen V Milev; Arun Ravindran; Claire O'Donovan; Diane McIntosh; Raymond W Lam; Gustavo Vazquez; Flavio Kapczinski; Roger S McIntyre; Jan Kozicky; Shigenobu Kanba; Beny Lafer; Trisha Suppes; Joseph R Calabrese; Eduard Vieta; Gin Malhi; Robert M Post; Michael Berk
Journal:  Bipolar Disord       Date:  2018-03-14       Impact factor: 6.744

2.  Exploring the risk-factor association between depression and incident stroke: a systematic review and meta-analysis.

Authors:  Kristian Barlinn; Jessica Kepplinger; Volker Puetz; Ben M Illigens; Ulf Bodechtel; Timo Siepmann
Journal:  Neuropsychiatr Dis Treat       Date:  2014-12-18       Impact factor: 2.570

3.  Association between hyperuricemia and metabolic syndrome in patients suffering from bipolar disorder.

Authors:  Jingxu Chen; Hongmei Chen; Junhui Feng; Ligang Zhang; Juyan Li; Ran Li; Shaoli Wang; Ian Wilson; Alison Jones; Yunlong Tan; Fude Yang; Xu-Feng Huang
Journal:  BMC Psychiatry       Date:  2018-12-18       Impact factor: 3.630

4.  Obesity and metabolic comorbidity in bipolar disorder: do patients on lithium comprise a subgroup? A naturalistic study.

Authors:  Jake Prillo; Jocelyn Fotso Soh; Outi Linnaranta; Soham Rej; Haley Park; Serge Beaulieu
Journal:  BMC Psychiatry       Date:  2021-11-10       Impact factor: 3.630

5.  A Longitudinal Study of the Association between the LEPR Polymorphism and Treatment Response in Patients with Bipolar Disorder.

Authors:  Hui Hua Chang; Yuan-Shuo Hsueh; Yung Wen Cheng; Huai-Hsuan Tseng
Journal:  Int J Mol Sci       Date:  2022-08-25       Impact factor: 6.208

6.  Nutrition, Exercise, and Wellness Treatment in bipolar disorder: proof of concept for a consolidated intervention.

Authors:  Louisa G Sylvia; Stephanie Salcedo; Emily E Bernstein; Ji Hyun Baek; Andrew A Nierenberg; Thilo Deckersbach
Journal:  Int J Bipolar Disord       Date:  2013-10-01

7.  Impact of metabolic syndrome and clinical features on functioning in patients with bipolar disorder: a cross-sectional study.

Authors:  Hanife Kocakaya; Emrah Songur; Sedat Batmaz; Zekiye Çelikbaş; Önder Küçük
Journal:  Braz J Psychiatry       Date:  2020-03-16       Impact factor: 2.697

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.